Brokers Offer Predictions for Oncobiologics FY2026 Earnings

Key Points

• Ascendiant Capital Markets raised its FY2026 EPS estimate for Oncobiologics to a loss of $0.45 per share from $0.51, while maintaining a Buy rating and $10 price target. The broader analyst consensus is a $0.47-per-share loss and a Hold rating with an average target of $5.20.
• Oncobiologics reported a quarterly loss of $0.09 per share, missing the $0.08 consensus estimate, while revenue of $0.01 million fell well short of the $0.97 million forecast.
• The stock opened at $0.68 and has traded between $0.16 and $2.54 over the past year. Insider buying included a director’s approximately $2.5 million purchase, while institutional investors own 11.2% of the company.

Oncobiologics, Inc. (NASDAQ:OTLK - Free Report) - Investment analysts at Ascendiant Capital Markets lifted their FY2026 earnings per share estimates for shares of Oncobiologics in a research report issued on Thursday, September 10th. Ascendiant Capital Markets analyst E. Woo now expects that the company will earn ($0.45) per share for the year, up from their previous estimate of ($0.51). Ascendiant Capital Markets has a "Buy" rating and a $10.00 price target on the stock. The consensus estimate for Oncobiologics' current full-year earnings is ($0.47) per share. Ascendiant Capital Markets also issued estimates for Oncobiologics' Q4 2026 earnings at ($0.08) EPS, Q1 2027 earnings at ($0.08) EPS, Q2 2027 earnings at ($0.07) EPS, Q3 2027 earnings at ($0.06) EPS, Q4 2027 earnings at ($0.06) EPS and FY2027 earnings at ($0.27) EPS.

A number of other analysts have also recently weighed in on the stock. Weiss Ratings raised shares of Oncobiologics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Wednesday, August 12th. HC Wainwright upped their target price on shares of Oncobiologics to $1.60 and gave the company a "neutral" rating in a report on Monday, July 27th. Wall Street Zen lowered shares of Oncobiologics from a "hold" rating to a "sell" rating in a research note on Saturday, August 15th. Finally, BTIG Research reissued a "buy" rating and issued a $4.00 price target on shares of Oncobiologics in a research report on Friday, August 14th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Oncobiologics has an average rating of "Hold" and an average target price of $5.20.

Oncobiologics Stock Up 0.6%

Oncobiologics stock opened at $0.68 on Thursday. Oncobiologics has a 52-week low of $0.16 and a 52-week high of $2.54. The firm has a market cap of $164.79 million, a PE ratio of -0.88 and a beta of 0.74. The company's 50 day moving average is $0.95 and its two-hundred day moving average is $0.74.

Oncobiologics (NASDAQ:OTLK - Get Free Report) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.01). The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.97 million.

Institutional Investors Weigh In On Oncobiologics

A hedge fund recently bought a new position in Oncobiologics stock. NewEdge Advisors LLC purchased a new position in shares of Oncobiologics, Inc. (NASDAQ:OTLK - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 16,722 shares of the company's stock, valued at approximately $27,000. 11.20% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Faisal Ghiath Sukhtian acquired 95,398 shares of the firm's stock in a transaction dated Wednesday, July 29th. The stock was acquired at an average cost of $1.05 per share, with a total value of $100,167.90. Following the completion of the acquisition, the director owned 220,972 shares of the company's stock, valued at $232,020.60. The trade was a 75.97% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ghiath Sukhtian bought 2,525,252 shares of the stock in a transaction dated Wednesday, August 12th. The shares were acquired at an average price of $0.99 per share, for a total transaction of $2,499,999.48. Following the completion of the transaction, the director owned 24,617,320 shares of the company's stock, valued at approximately $24,371,146.80. The trade was a 11.43% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 1.80% of the stock is currently owned by insiders.

Oncobiologics Company Profile

Oncobiologics, Inc, now known as Outlook Therapeutics, Inc NASDAQ: OTLK, is a biopharmaceutical company focused on developing and commercializing ophthalmic medicines. The company specializes in biologic therapies intended to address diseases affecting the eye, with an emphasis on retinal disorders.

The company's lead product is ONS-5010, an ophthalmic formulation of bevacizumab developed for intravitreal treatment of wet age-related macular degeneration and other retinal conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.